Clinical Trial Detail

NCT ID NCT02201212
Title Everolimus for Cancer With TSC1 or TSC2 Mutation
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

Advanced Solid Tumor

Therapies

Everolimus

Age Groups: adult

Additional content available in CKB BOOST